Data / Drug companies / Ethosuximide
Ethosuximide: 9 companies and 12 products in the FDA NDC directory
Ethosuximide is listed in the FDA National Drug Code Directory by 9 companies, with 12 products in commercial distribution. 11 of the products (91.7%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are capsule; solution; capsule, liquid filled, and the newest product started marketing on November 12, 2021.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 9
- Products
- 12
- Generic (ANDA) products
- 11 (91.7%)
- Application numbers
- 8
- Routes
- Oral
- Brand names
- Zarontin
- openFDA record search
- api.fda.gov
Companies that list ethosuximide
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Chartwell RX, LLC | 2 | solution; capsule | Generic drugs (ANDA) | September 9, 2015 |
| Epic Pharma, LLC | 2 | capsule | Generic drugs (ANDA) | November 12, 2021 |
| Parke-Davis Div of Pfizer Inc | 2 | capsule; solution | New drug applications (NDA) | March 10, 2020 |
| Bionpharma Inc. | 1 | capsule, liquid filled | Generic drugs (ANDA) | October 21, 2016 |
| Bryant Ranch Prepack | 1 | capsule, liquid filled | Generic drugs (ANDA) | October 21, 2016 |
| Chartwell Governmental & Specialty RX, LLC. | 1 | solution | Generic drugs (ANDA) | December 22, 2003 |
| Mylan Pharmaceuticals Inc. | 1 | solution | Generic drugs (ANDA) | February 21, 2020 |
| Pai Holdings, LLC DBA Pai Pharma | 1 | solution | Generic drugs (ANDA) | November 22, 2000 |
| Strides Pharma Science Limited | 1 | capsule | Generic drugs (ANDA) | May 15, 2019 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 5 | 41.7% |
| Solution | 5 | 41.7% |
| Capsule, liquid filled | 2 | 16.7% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 11 | 91.7% |
| New drug applications (NDA) | 1 | 8.3% |
Pharmacologic classes
| Class | Products |
|---|---|
| Anti-epileptic Agent | 12 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.